Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer
Authors
Zhou, SHawley, JR
Soares, F
Grillo, G
Teng, M
Madani, Tonekaboni SA
Hua, JT
Kron, KJ
Mazrooei, P
Ahmed, M
Arlidge, C
Yun, HY
Livingstone, J
Huang, V
Yamaguchi, TN
Espiritu, SMG
Zhu, Y
Severson, TM
Murison, A
Cameron, S
Zwart, W
Van der Kwast, T
Pugh, TJ
Fraser, M
Boutros, PC
Bristow, Robert G
He, HH
Lupien, M
Affiliation
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CanadaIssue Date
2020
Metadata
Show full item recordAbstract
Prostate cancer is the second most commonly diagnosed malignancy among men worldwide. Recurrently mutated in primary and metastatic prostate tumors, FOXA1 encodes a pioneer transcription factor involved in disease onset and progression through both androgen receptor-dependent and androgen receptor-independent mechanisms. Despite its oncogenic properties however, the regulation of FOXA1 expression remains unknown. Here, we identify a set of six cis-regulatory elements in the FOXA1 regulatory plexus harboring somatic single-nucleotide variants in primary prostate tumors. We find that deletion and repression of these cis-regulatory elements significantly decreases FOXA1 expression and prostate cancer cell growth. Six of the ten single-nucleotide variants mapping to FOXA1 regulatory plexus significantly alter the transactivation potential of cis-regulatory elements by modulating the binding of transcription factors. Collectively, our results identify cis-regulatory elements within the FOXA1 plexus mutated in primary prostate tumors as potential targets for therapeutic intervention.Citation
Zhou S, Hawley JR, Soares F, Grillo G, Teng M, Madani Tonekaboni SA, et al. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nat Commun. 2020;11(1):441.Journal
Nature CommunicationsDOI
10.1038/s41467-020-14318-9PubMed ID
31974375Additional Links
https://dx.doi.org/10.1038/s41467-020-14318-9Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41467-020-14318-9
Scopus Count
Collections
Related articles
- Pioneer of prostate cancer: past, present and the future of FOXA1.
- Authors: Teng M, Zhou S, Cai C, Lupien M, He HH
- Issue date: 2021 Jan
- Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
- Authors: Tam KJ, Liu L, Hsing M, Dalal K, Thaper D, McConeghy B, Yenki P, Bhasin S, Peacock JW, Wang Y, Cherkasov A, Rennie PS, Gleave ME, Ong CJ
- Issue date: 2024 Mar 25
- Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
- Authors: Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A, Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML
- Issue date: 2021 Mar 30
- Re: Noncoding Mutations Target Cis-Regulatory Elements of the FOXA1 Plexus in Prostate Cancer.
- Authors: Atala A
- Issue date: 2020 Nov
- Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
- Authors: Parolia A, Cieslik M, Chu SC, Xiao L, Ouchi T, Zhang Y, Wang X, Vats P, Cao X, Pitchiaya S, Su F, Wang R, Feng FY, Wu YM, Lonigro RJ, Robinson DR, Chinnaiyan AM
- Issue date: 2019 Jul